The Psychedelic Therapy Podcast14 Tammi 2022

Jonathan Dickinson (Ceiba Recovery): Iboga, Initiation, and Long-Haul Healing

Iboga (or its extraction ibogaine) is one of the most powerful psychedelic plants. Today we are joined by Jonathan Dickinson, of Ceiba Recovery, an integration coach and consultant for iboga and ibogaine healing.

Our conversation begins with an overview of iboga and its unique value in treating addiction. We discuss Bwiti tradition in Gabon and Central Africa, where iboga is used as an initiatory sacrament. Jonathan shares his work with Ceiba Recovery, which includes online ibogaine aftercare. We conclude with the pros and cons of a clinical ibogaine setting vs the traditional iboga initiation, as well as general advice on integrating this powerful medicine.

Jonathan is a recovery coach and consultant and has been working with iboga and ibogaine in both clinical and ceremonial contexts in Canada, Mexico, and Costa Rica since 2009. He has been part of hundreds of detox treatments and has also coached people through long-term micro-dosing protocols for everything from depression and anxiety to neurodegenerative disorders. He previously served as the Director of the Global Ibogaine Therapy Alliance (GITA), during which time he led the development of the Clinical Guidelines for Ibogaine-Assisted Detoxification, a risk management guide that remains a standard in the field.

Links

Timestamps

:07 - What is iboga and what does the experience feel like?
:16 - Iboga as a sacrament for initiation
:27 - Jonathan’s process from initial interest to aftercare coaching and support of iboga
:32 - Protecting the local community and sustainable farming in Gabon
:34 - Ceiba, addiction, and the stages of change model
:44 - Iboga in a clinical setting vs traditional initiation
:50 - Dealing with Iboga’s long integration

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(64)

Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali...

21 Huhti 1h 10min

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that...

25 Huhti 202555min

Joshua White: Who You Gonna Call? Fireside

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer sup...

13 Helmi 20251h 14min

Tom Feegel: Ibogaine for Cognitive Enhancement

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remark...

27 Tammi 20251h 6min

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of car...

20 Marras 20241h 4min

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of...

28 Loka 20241h 3min

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, orig...

18 Loka 20241h 9min

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the differe...

8 Elo 202446min